New platform aims to personalize cancer treatment for GI patients

NCT ID NCT04724070

Ongoing Knowledge-focused Sponsor: Brigette Ma Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived cancer models to test drugs. The goal is to improve treatment matching and build a biobank for future research.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could create a personalized drug screening system to better match treatments to individual patients with advanced gastrointestinal cancers.
What could go wrong: This is an observational platform study, not a treatment trial. It focuses on building tools and collecting data, so direct patient benefits are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer digestive system cancer digestive system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL CANCERS

Contacts and locations

Locations

The Chinese University of Hong Kong

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.